These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 25036722)

  • 21. Selection and characterization of a high-activity ribozyme directed against the antineoplastic drug resistance-associated ABC transporter BCRP/MXR/ABCG2.
    Kowalski P; Wichert A; Holm PS; Dietel M; Lage H
    Cancer Gene Ther; 2001 Mar; 8(3):185-92. PubMed ID: 11332989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).
    Gupta A; Zhang Y; Unadkat JD; Mao Q
    J Pharmacol Exp Ther; 2004 Jul; 310(1):334-41. PubMed ID: 15007102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Scaffold identification of a new class of potent and selective BCRP inhibitors.
    Marighetti F; Steggemann K; Karbaum M; Wiese M
    ChemMedChem; 2015 Apr; 10(4):742-51. PubMed ID: 25735648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
    Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breast cancer resistance protein (BCRP/ABCG2).
    Staud F; Pavek P
    Int J Biochem Cell Biol; 2005 Apr; 37(4):720-5. PubMed ID: 15694832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).
    Juvale K; Gallus J; Wiese M
    Bioorg Med Chem; 2013 Dec; 21(24):7858-73. PubMed ID: 24184213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
    Ji N; Yuan J; Liu J; Tian S
    Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human ABC transporter ABCG2 in cancer chemotherapy: drug molecular design to circumvent multidrug resistance.
    Ishikawa T; Saito H; Hirano H; Inoue Y; Ikegami Y
    Methods Mol Biol; 2012; 910():267-78. PubMed ID: 22821599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Computational classification models for predicting the interaction of drugs with P-glycoprotein and breast cancer resistance protein.
    Erić S; Kalinić M; Ilić K; Zloh M
    SAR QSAR Environ Res; 2014; 25(12):939-66. PubMed ID: 25435255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
    Shen H; Lee FY; Gan J
    J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation.
    Haimeur A; Conseil G; Deeley RG; Cole SP
    Curr Drug Metab; 2004 Feb; 5(1):21-53. PubMed ID: 14965249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
    Pick A; Wiese M
    ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics.
    Jani M; Ambrus C; Magnan R; Jakab KT; Beéry E; Zolnerciks JK; Krajcsi P
    Arch Toxicol; 2014 Jun; 88(6):1205-48. PubMed ID: 24777822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.
    Miwa M; Tsukahara S; Ishikawa E; Asada S; Imai Y; Sugimoto Y
    Int J Cancer; 2003 Dec; 107(5):757-63. PubMed ID: 14566825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2).
    Ahmed-Belkacem A; Pozza A; Macalou S; Pérez-Victoria JM; Boumendjel A; Di Pietro A
    Anticancer Drugs; 2006 Mar; 17(3):239-43. PubMed ID: 16520651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
    Graber-Maier A; Gutmann H; Drewe J
    Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells.
    Sampson KE; Brinker A; Pratt J; Venkatraman N; Xiao Y; Blasberg J; Steiner T; Bourner M; Thompson DC
    Drug Metab Dispos; 2015 Feb; 43(2):199-207. PubMed ID: 25388687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2).
    Janvilisri T; Shahi S; Venter H; Balakrishnan L; van Veen HW
    Biochem J; 2005 Jan; 385(Pt 2):419-26. PubMed ID: 15362954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
    Imai Y; Yoshimori M; Fukuda K; Yamagishi H; Ueda Y
    Oncol Rep; 2012 Jun; 27(6):1703-9. PubMed ID: 22426819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCRP/ABCG2 inhibitors: a patent review (2009-present).
    Wiese M
    Expert Opin Ther Pat; 2015; 25(11):1229-37. PubMed ID: 26291461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.